12,372 trials
Chronic Kidney Disease (CKD) · Hyperkalemia (HK)
Primary: Change in Serum Potassium From Part A Baseline to Part A Week 4 — -1.01 mEq/L — p=<0.001
Binge Eating Disorder
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as a Measure of Safety — 84.5; 2.8 percentage of participants
Perennial Allergic Rhinitis
Primary: Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation) — -0.84; -0.92; -0.70 units on…
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Gaucher Disease
Primary: Spleen Volume — 2032.0; 1960.0; 2321.7; 1522.6 Milliliters
Perennial Allergic Rhinitis
Primary: Number of Patients With Adverse Events and Adverse Drug Reactions — 37; 2 participants
Gaucher Disease
Primary: Number of Participants With Drug-related Adverse Events (AEs), Infusion-related AEs, and Serious AEs (SAEs) — 2; 0; 2 participants
Non-Squamous Non-Small Cell Lung Cancer
Primary: Median Progression Free Survival (PFS) Time — 6.0; 7.6 months — p=<0.0001
Constipation
Primary: Change of the SBMs From Baseline at Week 4 — 2.7; 2.7; 2.2; 2.4 times per week — p=0.352
Critically Ill
Primary: SOFA (Sequential Organ Failure Assessment) Score — 0.7; 1.7 units on a scale
Multiple Myeloma
Primary: Progression-free Survival — 9.4; 18.7 months — p=< 0.0001
Breast Cancer
Primary: Disease-free Survival — 74.7; 78.1 percentage of participants — p=0.14
Influenza
Primary: 1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c — 60.7; 59.6; NA; 302.8 Titer
Lymphoma, Follicular
Primary: Event-free Survival — 53.944 months
Chronic Myeloid Leukemia
Primary: Major Molecular Response (MMR) at 12 Months - With Imputation. — 27.8; 52.2 Percentage of Participants — p=0.0001